Cargando…
COVID-19 associated complications and potential therapeutic targets
The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486300/ https://www.ncbi.nlm.nih.gov/pubmed/32926918 http://dx.doi.org/10.1016/j.ejphar.2020.173548 |
_version_ | 1783581310599561216 |
---|---|
author | Monpara, Jasmin D. Sodha, Srushti J. Gupta, Pardeep K. |
author_facet | Monpara, Jasmin D. Sodha, Srushti J. Gupta, Pardeep K. |
author_sort | Monpara, Jasmin D. |
collection | PubMed |
description | The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19. |
format | Online Article Text |
id | pubmed-7486300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74863002020-09-14 COVID-19 associated complications and potential therapeutic targets Monpara, Jasmin D. Sodha, Srushti J. Gupta, Pardeep K. Eur J Pharmacol Full Length Article The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19. Elsevier B.V. 2020-11-05 2020-09-12 /pmc/articles/PMC7486300/ /pubmed/32926918 http://dx.doi.org/10.1016/j.ejphar.2020.173548 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Full Length Article Monpara, Jasmin D. Sodha, Srushti J. Gupta, Pardeep K. COVID-19 associated complications and potential therapeutic targets |
title | COVID-19 associated complications and potential therapeutic targets |
title_full | COVID-19 associated complications and potential therapeutic targets |
title_fullStr | COVID-19 associated complications and potential therapeutic targets |
title_full_unstemmed | COVID-19 associated complications and potential therapeutic targets |
title_short | COVID-19 associated complications and potential therapeutic targets |
title_sort | covid-19 associated complications and potential therapeutic targets |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486300/ https://www.ncbi.nlm.nih.gov/pubmed/32926918 http://dx.doi.org/10.1016/j.ejphar.2020.173548 |
work_keys_str_mv | AT monparajasmind covid19associatedcomplicationsandpotentialtherapeutictargets AT sodhasrushtij covid19associatedcomplicationsandpotentialtherapeutictargets AT guptapardeepk covid19associatedcomplicationsandpotentialtherapeutictargets |